FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385702561> ?p ?o ?g. }

• W4385702561 endingPage "e995514a" @default.
• W4385702561 startingPage "e995514a" @default.
• W4385702561 abstract "Topic: 24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research Background: The evolution of gene therapy has led to the development of innovative therapeutic strategies for beta-hemoglobinopathies, including the gene addition of beta- or gamma-globin gene or the induction of HbF reactivation. Notwithstanding the promising results emerged from the lentiviral vector gene therapy using autologous hematopoietic stem cells(HSCs), some limitations still exist. Incorporation of the long in size β-LCR(~3 kb), to enhance transgene expression results in low viral titers and reduced transducibility of HSCs, thus negatively affecting efficiency and the overall cost. Aims: The main scope of the present study was to explore our previously published high-resolution temporal atlas of developmentally responsive DNase I hypersensitive sites during human adult erythropoiesis, to identify novel strong, compact, erythroid specific enhancers able to challenge the canonical enhancer of beta-hemoglobinopathy-vectors, β-LCR. Methods: We performed a FACS-based MPRA assay to interrogate the enhancer ability of a library of 15,000 candidate genomic sequences. Among these sequences ~6000 were shown to bare enhancer activity. A subset of these elements was then tested individually and the new enhancers displayed in vitro and in vivo erythroid specificity coupled with a broad range of temporal activity. Two of these enhancers were selected and cloned into a BCL11A-shRNA lentiviral vector to be compared with the micro β-LCR. The new vectors’ efficiency was evaluated in an erythroid cell line, in healthy, beta-thalassemia major- and sickle cell disease- derived CD34+ cells in vitro and in vivo. Results: The novel enhancers yielded a 2-5 fold increase in viral titers during production compared to the uLCR respective vector and exhibited elevated transduction levels in an immortalized erythroid progenitor cell line. Within the transduced populations γ-globin expression was equally increased in all groups compared to untransduced cells(p<0.004 in all vs untransduced). Following transduction with NE-shRNA or uLCR-shRNA vector, CD34+ cells from 5 thalassemic patients were cultured under erythroid differentiation conditions. At the end of the culture we observed a significantly increase of HbF+ cells (%) within the enucleated cells population, with the difference being higher in the case of the NE transduced cells (p=0.009 NE-shRNA and p=0.02 μLCR-shRNA vs untransduced cells). Additionally, we observed increased gamma globin production (α/γ-globin:p=0.024 and p=0.36, μLCR and NE vs untransduced) that resulted in an almost complete restoration of the imbalance between alpha and beta-like globins (beta-like/a-globin:p=0.036 NE-shRNA vs p=0.024 μLCR-shRNA). The elevated HbF levels reduced the oxidative stress in both transduced groups and improved both cell expansion and erythroid differentiation and maturation. Similar results were observed after transduction and erythroid differentiation of non mobilized SCD-derived HSPCs. Specifically, increased gamma globin chain production and reduction of βς -globin to a-globin ratio was observed only in the case of NE-shRNA transduced cells. Summary/Conclusion: Collectively, our data provide evidence that the replacement of μLCR by a novel, compact erythroid enhancer, is feasible and successful, leading to at least equally efficient transgene expression and HbF induction in both thalassemic and SCD erythroid cells. Overall, the new viral vectors are able to address the current issues of low viral titers, low HSC transducibility, in vivo performance and effect in cells from patients still seeking a robust and radical therapy. Keywords: Hematopoietic stem cell, Gene therapy, beta thalassemia" @default.
• W4385702561 created "2023-08-10" @default.
• W4385702561 creator A5000140761 @default.
• W4385702561 creator A5006847496 @default.
• W4385702561 creator A5017326948 @default.
• W4385702561 creator A5031342042 @default.
• W4385702561 creator A5031403968 @default.
• W4385702561 creator A5050713062 @default.
• W4385702561 creator A5061933115 @default.
• W4385702561 creator A5063440051 @default.
• W4385702561 creator A5073229066 @default.
• W4385702561 creator A5080209064 @default.
• W4385702561 creator A5081877050 @default.
• W4385702561 creator A5089992014 @default.
• W4385702561 creator A5092028234 @default.
• W4385702561 creator A5092614125 @default.
• W4385702561 date "2023-08-01" @default.
• W4385702561 modified "2023-10-11" @default.
• W4385702561 title "P1358: MINING THE GENOME FOR ERYTHROID SPECIFIC ENHANCERS TO OPTIMIZE GENE THERAPY VECTORS FOR BETA-HEMOGLOBINOPATHIES" @default.
• W4385702561 doi "https://doi.org/10.1097/01.hs9.0000972320.99551.4a" @default.
• W4385702561 hasPublicationYear "2023" @default.
• W4385702561 type Work @default.
• W4385702561 citedByCount "0" @default.
• W4385702561 crossrefType "journal-article" @default.
• W4385702561 hasAuthorship W4385702561A5000140761 @default.
• W4385702561 hasAuthorship W4385702561A5006847496 @default.
• W4385702561 hasAuthorship W4385702561A5017326948 @default.
• W4385702561 hasAuthorship W4385702561A5031342042 @default.
• W4385702561 hasAuthorship W4385702561A5031403968 @default.
• W4385702561 hasAuthorship W4385702561A5050713062 @default.
• W4385702561 hasAuthorship W4385702561A5061933115 @default.
• W4385702561 hasAuthorship W4385702561A5063440051 @default.
• W4385702561 hasAuthorship W4385702561A5073229066 @default.
• W4385702561 hasAuthorship W4385702561A5080209064 @default.
• W4385702561 hasAuthorship W4385702561A5081877050 @default.
• W4385702561 hasAuthorship W4385702561A5089992014 @default.
• W4385702561 hasAuthorship W4385702561A5092028234 @default.
• W4385702561 hasAuthorship W4385702561A5092614125 @default.
• W4385702561 hasBestOaLocation W43857025611 @default.
• W4385702561 hasConcept C102230213 @default.
• W4385702561 hasConcept C104317684 @default.
• W4385702561 hasConcept C111599444 @default.
• W4385702561 hasConcept C111936080 @default.
• W4385702561 hasConcept C125996951 @default.
• W4385702561 hasConcept C150194340 @default.
• W4385702561 hasConcept C153911025 @default.
• W4385702561 hasConcept C32470452 @default.
• W4385702561 hasConcept C40767141 @default.
• W4385702561 hasConcept C54355233 @default.
• W4385702561 hasConcept C70721500 @default.
• W4385702561 hasConcept C86803240 @default.
• W4385702561 hasConceptScore W4385702561C102230213 @default.
• W4385702561 hasConceptScore W4385702561C104317684 @default.
• W4385702561 hasConceptScore W4385702561C111599444 @default.
• W4385702561 hasConceptScore W4385702561C111936080 @default.
• W4385702561 hasConceptScore W4385702561C125996951 @default.
• W4385702561 hasConceptScore W4385702561C150194340 @default.
• W4385702561 hasConceptScore W4385702561C153911025 @default.
• W4385702561 hasConceptScore W4385702561C32470452 @default.
• W4385702561 hasConceptScore W4385702561C40767141 @default.
• W4385702561 hasConceptScore W4385702561C54355233 @default.
• W4385702561 hasConceptScore W4385702561C70721500 @default.
• W4385702561 hasConceptScore W4385702561C86803240 @default.
• W4385702561 hasIssue "S3" @default.
• W4385702561 hasLocation W43857025611 @default.
• W4385702561 hasLocation W43857025612 @default.
• W4385702561 hasOpenAccess W4385702561 @default.
• W4385702561 hasPrimaryLocation W43857025611 @default.
• W4385702561 hasRelatedWork W1550101598 @default.
• W4385702561 hasRelatedWork W1565635735 @default.
• W4385702561 hasRelatedWork W1581704829 @default.
• W4385702561 hasRelatedWork W2009966535 @default.
• W4385702561 hasRelatedWork W2063494976 @default.
• W4385702561 hasRelatedWork W2074705199 @default.
• W4385702561 hasRelatedWork W2147725961 @default.
• W4385702561 hasRelatedWork W2606105109 @default.
• W4385702561 hasRelatedWork W2759271641 @default.
• W4385702561 hasRelatedWork W4385702561 @default.
• W4385702561 hasVolume "7" @default.
• W4385702561 isParatext "false" @default.
• W4385702561 isRetracted "false" @default.
• W4385702561 workType "article" @default.